All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Knowledge Gap Remains for Sequencing of Later-Line Treatments of Advanced RCC

July 14th 2023

Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.

Leveraging Biology to Guide First-Line Treatment of Clear Cell RCC

July 14th 2023

Determining the appropriate front-line treatment pathway for patients with clear cell renal cell carcinoma may not always align with risk stratification features.

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14th 2023

Neoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages

July 14th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC

July 14th 2023

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

Sylvester Cancer Researcher Honored with ASCO Early Career Award

July 14th 2023

Shria Kumar, MD, a colorectal cancer researcher with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has been awarded a Conquer Cancer Career Development Award from the American Society of Clinical Oncology.

FLX475 Alters TME to Enhance Anti–PD-1/PD-L1 Response in NK/T-cell Lymphoma

July 13th 2023

Single-agent treatment with the novel CCR4 antagonist FLX475 led to changes in the tumor microenvironment to a phenotype more associated with responses to anti–PD-1/PD-L1 therapy in patients with natural killer/T-cell lymphoma.

Key Trials at ASCO 2023 Highlight Role of Perioperative Treatment Approaches in NSCLC

July 13th 2023

Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.

Despite Diagnostic Challenges, ADCs Are Poised to Expand Treatment Options in Lung Cancer

July 13th 2023

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

First-line Enfortumab Vedotin Plus Pembrolizumab Has Durable Activity in Urothelial Carcinoma

July 13th 2023

Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.

PROSPECT Trial Looks to Add Effective Option for Patients With R/R PCNSL

July 13th 2023

Efforts to develop the first FDA-approved agent specifically for patients with primary central nervous system lymphoma have been initiated with the phase 2 PROSPECT trial.

DKN-01 Plus Bevacizumab/Chemotherapy Advances to Part B in DeFianCe Trial in Advanced CRC

July 13th 2023

Leap Therapeutics has launched the randomized, controlled part B of the phase 2 DeFianCe trial, which will evaluate DKN-01 in combination with bevacizumab and chemotherapy as second-line therapy in patients with advanced colorectal cancer.

Novel Radiotherapy Supports Precision Medicine Advances in Lung and Bone Cancers

July 13th 2023

Adnan F. Danish, MD, discusses current unmet needs in the treatment of patients with stage IV lung and bone cancers, the benefits SCINTIX technology can provide for these patients, and how John Theurer Cancer Center plans to use this technology to improve patient outcomes and support further radiation therapy research.

Datopotamab Deruxtecan Plus Pembrolizumab Displays Efficacy in Advanced NSCLC With or Without Chemotherapy

July 12th 2023

Yasushi Goto, MD, PhD, delves into the details of the TROPION-Lung02 trial.

China’s NMPA Accepts sNDA for Frontline Toripalimab Plus Axitinib in Metastatic RCC

July 12th 2023

China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab plus for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma

Anemia-Focused Treatment Approaches Represent Future Directions in Myelofibrosis

July 12th 2023

Anna B. Halpern, MD, discusses strides in the treatment of myelofibrosis with anemia, the shifting role of ruxolitinib in this disease, and the importance of providing patients with access to clinical trials.

BASECAMP-1 Trial Aims to Identify Patients for Subsequent Treatment Trial of CAR T-Cell Therapy in Solid Tumors

July 12th 2023

Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert and dives into the unique mechanism of action of A2B530.

Trastuzumab Deruxtecan Approved in China for HER2-Low Metastatic Breast Cancer

July 12th 2023

China’s National Medical Products Administration has approved trastuzumab deruxtecan monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer who have previously received a systemic therapy in the metastatic setting or whose disease recurred during or within 6 months of adjuvant chemotherapy.

Researcher at Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center Awarded $450,000 Grant for Breast Cancer Work

July 12th 2023

Lucia Borriello, PhD, an assistant professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University and a member of the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, has been awarded a three-year $450,000 research grant from Susan G. Komen.

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

July 12th 2023

The FDA has accepted a supplemental biologics license application seeking the approval of zanubrutinib in combination with obinutuzumab in the treatment of adult patients with relapsed/refractory follicular lymphoma who received at least 2 prior lines of therapy.